Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition
分子靶向放射性核素治疗增强肿瘤细胞对免疫检查点抑制的敏感性和反应
基本信息
- 批准号:10263247
- 负责人:
- 金额:$ 39.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-14 至 2025-05-31
- 项目状态:未结题
- 来源:
- 关键词:90YAbbreviationsAffectAlpha ParticlesAntigen PresentationAntigensAntitumor ResponseBeta ParticleCancer PatientCellsClinical ResearchClinical SensitivityClinical TrialsClonal ExpansionControlled StudyDiagnostic radiologic examinationDiseaseDisseminated Malignant NeoplasmDoseDose-RateElectronsExternal Beam Radiation TherapyFeedbackGamma RaysGene Expression ProfilingGenerationsGenetically Engineered MouseGoalsHalf-LifeImageImmuneImmune checkpoint inhibitorImmune responseImmune systemImmunologic MemoryImmunologicsImmunotherapyIndividualInflammationInterferon Type IInterferonsLinear Energy TransferLocationMalignant neoplasm of prostateMeasurementMediatingModelingMolecular TargetMonitorMusNeuroblastomaOrganismOutcomePathway interactionsPatientsPredispositionProductionRadiationRadiation therapyRadioactiveRadioisotopesRadionuclide therapyRegulatory T-LymphocyteScanningSiteStimulator of Interferon GenesT cell clonalityT cell responseT-cell receptor repertoireTREX1 geneTestingTherapeuticThree Prime Repair Exonuclease 1Toxic effectTranslationsTreatment ProtocolsTumor AntigensTumor ImmunityTumor-Infiltrating LymphocytesTumor-infiltrating immune cellsVariantVeinsVirus DiseasesWhole-Body Irradiationanti-CTLA4anti-PD-1anti-tumor immune responsecancer therapycheckpoint inhibitionclinically relevantds-DNAeffectiveness testingfollow-upimmunogenic cell deathimmunoregulationimprovedin situ vaccinein vivoinsightmelanomamultidisciplinaryneoplastic cellnext generationpreclinical studyprospectiveresearch clinical testingresponsetargeted treatmenttumortumor microenvironmentvector
项目摘要
PROJECT SUMMARY – PROJECT 2
In a project that builds upon the ongoing collaborative progress of our multidisciplinary team, we will
systematically evaluate mechanisms of cooperative interaction and optimize the potency of treatment regimens
that combine targeted radionuclide therapies (TRT) with immune checkpoint inhibition (ICI; e.g. anti-PD-
1, anti-CTLA-4) to enhance the anti-tumor immune response against metastatic cancers. Moderate dose
(8-12 Gy) external beam radiation therapy (EBRT) is capable of eliciting an in situ vaccine effect, converting the
targeted tumor into a nidus for enhanced tumor antigen recognition. In preclinical and clinical studies, this results
in diversification of the T cell receptor (TCR) repertoire. Consequently, in preclinical studies, EBRT improves the
response to ICIs. This is at least in part dependent upon the capacity of EBRT to activate a type I interferon (IFN)
response in radiated tumor cells. However, clinical studies have not yet conclusively demonstrated a benefit from
combining EBRT with ICIs, and even in studies that suggest a benefit it is clear that more is needed if we aim to
develop an effective approach to eradicating metastatic disease for all cancer patients. In pursuit of such a goal,
we now propose to evaluate a next generation strategy to leveraging the capacity of radiation to enhance
response to ICIs by using TRTs to deliver radiation to all tumor sites in settings of metastatic disease. To begin
testing this approach, we will compare the relative capacities of different TRT agents to 1) activate a type I IFN
response in tumor cells, 2) augment response to ICIs, and 3) increase the diversity and clonality of the TCR
repertoire among tumor infiltrating lymphocytes. We hypothesize that TRT will enhance the rate and depth of
response to ICIs and that this will correlated with effects on the TCR repertoire that are dependent on the ability
of TRT to modulate tumor cell immune susceptibility by activating a type I IFN response. We expect that TRTs
will also elicit immunogenic cell death, local inflammation, and temporary depletion of suppressive regulatory T
cells (Tregs) from the tumor microenvironment (TME), and other Projects in this P01 will investigate those
mechanisms further. Here, we will compare the relative effects of TRT radionuclides and vectors in order to
develop a fundamental understanding of the interactions between these agents and anti-tumor immunity. In
particular, we will evaluate the potential impacts of tumor size, type, and number as well as the type of radioactive
decay products (e.g. α particle vs β particle vs γ-ray vs Auger electron), linear energy transfer (LET), dose, dose-
rate and half-life, and dose range. We will also examine the potential impact of the TRT vector, specifically testing
how changes in TRT distribution at the organism, tumor, and subcellular level affect anti-tumor immunity. The
insights and treatment regimens developed in these studies should enable rapid translation to clinical
testing in patients with any type of metastatic cancer while also launching a generation of follow-up
basic and translational preclinical studies.
项目总结-项目2
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Zachary Scott Morris其他文献
Zachary Scott Morris的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Zachary Scott Morris', 18)}}的其他基金
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response
分子靶向放射性核素治疗肿瘤免疫调节和增强免疫治疗反应
- 批准号:
10737774 - 财政年份:2020
- 资助金额:
$ 39.2万 - 项目类别:
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition
分子靶向放射性核素治疗增强肿瘤细胞对免疫检查点抑制的敏感性和反应
- 批准号:
10672926 - 财政年份:2020
- 资助金额:
$ 39.2万 - 项目类别:
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response
分子靶向放射性核素治疗肿瘤免疫调节和增强免疫治疗反应
- 批准号:
10672912 - 财政年份:2020
- 资助金额:
$ 39.2万 - 项目类别:
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response
分子靶向放射性核素治疗肿瘤免疫调节和增强免疫治疗反应
- 批准号:
10533542 - 财政年份:2020
- 资助金额:
$ 39.2万 - 项目类别:
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition
分子靶向放射性核素治疗增强肿瘤细胞对免疫检查点抑制的敏感性和反应
- 批准号:
10024882 - 财政年份:2020
- 资助金额:
$ 39.2万 - 项目类别:
Molecular Targeted Radionuclide Therapy to Enhance Tumor Cell Susceptibility and Response to Immune Checkpoint Inhibition
分子靶向放射性核素治疗增强肿瘤细胞对免疫检查点抑制的敏感性和反应
- 批准号:
10416046 - 财政年份:2020
- 资助金额:
$ 39.2万 - 项目类别:
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response
分子靶向放射性核素治疗肿瘤免疫调节和增强免疫治疗反应
- 批准号:
10024878 - 财政年份:2020
- 资助金额:
$ 39.2万 - 项目类别:
Molecular Targeted Radionuclide Therapy for Tumor Immunomodulation and Enhancing Immunotherapy Response
分子靶向放射性核素治疗肿瘤免疫调节和增强免疫治疗反应
- 批准号:
10263244 - 财政年份:2020
- 资助金额:
$ 39.2万 - 项目类别:
相似海外基金
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
- 批准号:
8077875 - 财政年份:2010
- 资助金额:
$ 39.2万 - 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
- 批准号:
7866149 - 财政年份:2010
- 资助金额:
$ 39.2万 - 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
- 批准号:
8589822 - 财政年份:2010
- 资助金额:
$ 39.2万 - 项目类别:
Real-time Disambiguation of Abbreviations in Clinical Notes
临床记录中缩写词的实时消歧
- 批准号:
8305149 - 财政年份:2010
- 资助金额:
$ 39.2万 - 项目类别: